After losing patent protection last year on the blockbuster antidepressant Lexapro, Danish drugmaker Lundbeck hopes to regain a least a bit of that vaporized revenue as it launches its anti-binge drinking drug Selincro in some European countries.
Lundbeck has rolled out a fresh set of positive data on its new antidepressant Brintellix (vortioxetine/Lu AA21004), this time offering up some head-to-head results to help position the drug in the marketplace.
Building on an earlier alliance, Otsuka has gained co-development and co-promotion rights in the U.S., Japan and Europe for Lu AE58054, an experimental Alzheimer's drug now in position for a looming pivotal program.
Lundbeck has another chance to crow this week, now that its once-monthly version of Abilify has FDA approval. The agency nod comes fast on the heels of another, for the Danish drugmaker's alcohol addiction drug Selincro. This double victory opens the way for Lundbeck to transform turnaround promises into actual sales.
Denmark's Lundbeck has won European approval for the alcohol dependence drug Selincro (nalmefene), a new approach to fighting addiction which it had in-licensed from Finland's Biotie. But don't expect to see it in the U.S. anytime soon.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
Björklund had been CEO at the Swiss drugmaker Nycomed, until it sold out to Takeda Pharmaceuticals in 2011.
Anyone who tells you that there's no such thing as bad publicity never worked in the pharma business.
According to the annual PatientView survey, 42% of patient groups in 56 countries rated pharma's reputation as "fair," while 25% called the industry's rep "poor."
Lundbeck's struggle to rebuild after the loss of its now-off-patent antidepressant Cipralex will take more of a toll on its finances than previously thought. The company has cut its outlook for 2013 and 2014, citing Europe's economic woes and its own R&D expenses.